Literature DB >> 23070811

Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.

Senthil K Muthuswamy1.   

Abstract

Prolactin (PRL) is a peptide hormone that is produced by the pituitary gland and is known to regulate lactogenic differentiation. There is a significant body of evidence that points to autocrine production of prolactin and activation of an autocrine/paracrine signaling pathway to regulate cell proliferation and migration and inhibition of cell death. This perspective highlights the recent study in the October 1, 2012, issue of Genes & Development by Chen and colleagues (pp. 2154-2168) that describes a mechanism for autocrine prolactin production and places the finding in the context of a role for prolactin in breast development and cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070811      PMCID: PMC3475797          DOI: 10.1101/gad.204636.112

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  60 in total

1.  Prolactin receptor gene expression in rat mammary gland and liver during pregnancy and lactation.

Authors:  G A Jahn; M Edery; L Belair; P A Kelly; J Djiane
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

2.  Prolactin as a chemoattractant for human breast carcinoma.

Authors:  M V Maus; S C Reilly; C V Clevenger
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

3.  Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.

Authors:  Y Huang; X Li; J Jiang; S J Frank
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

4.  PRL modulates cell cycle regulators in mammary tumor epithelial cells.

Authors:  Matthew D Schroeder; Jaime Symowicz; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2002-01

Review 5.  Prolactin involvement in breast cancer.

Authors:  B K Vonderhaar
Journal:  Endocr Relat Cancer       Date:  1999-09       Impact factor: 5.678

6.  JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization.

Authors:  H Rui; J J Lebrun; R A Kirken; P A Kelly; W L Farrar
Journal:  Endocrinology       Date:  1994-10       Impact factor: 4.736

7.  Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture.

Authors:  R Biswas; B K Vonderhaar
Journal:  Cancer Res       Date:  1987-07-01       Impact factor: 12.701

8.  Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture.

Authors:  W B Malarkey; M Kennedy; L E Allred; G Milo
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

9.  Prolactin activates the interferon-regulated p91 transcription factor and the Jak2 kinase by tyrosine phosphorylation.

Authors:  M David; E F Petricoin; K Igarashi; G M Feldman; D S Finbloom; A C Larner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

10.  Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells.

Authors:  I Dusanter-Fourt; O Muller; A Ziemiecki; P Mayeux; B Drucker; J Djiane; A Wilks; A G Harpur; S Fischer; S Gisselbrecht
Journal:  EMBO J       Date:  1994-06-01       Impact factor: 11.598

View more
  3 in total

Review 1.  Prolactin: The Third Hormone in Breast Cancer.

Authors:  Linda A Schuler; Kathleen A O'Leary
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

2.  Growth hormone is increased in the lungs and enhances experimental lung metastasis of melanoma in DJ-1 KO mice.

Authors:  Chia-Hung Chien; Ming-Jen Lee; Houng-Chi Liou; Horng-Huei Liou; Wen-Mei Fu
Journal:  BMC Cancer       Date:  2016-11-08       Impact factor: 4.430

3.  The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome.

Authors:  Doonyapat Sa-Nguanraksa; Cholladda Thasripoo; Norasate Samarnthai; Tanawan Kummalue; Thanawat Thumrongtaradol; Pornchai O-Charoenrat
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.